Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
- 87 Downloads
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.
The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.
We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?
The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited.
KeywordsMerkel cell carcinoma Neuroendocrine tumours Immune checkpoint inhibitors Avelumab Pembrolizumab Therapy
This review is part of the ‘NIKE’ project (Neuroendocrine tumours Innovation Knowledge and Education) led by Prof Annamaria Colao, which aims at increasing the knowledge on NETs. We would like to acknowledge all the Collaborators of this project: Manuela Albertelli, Barbara Altieri, Elena Ambrosetti, Antonio Bianchi, Lena Bottiglieri, Severo Campione, Silvia Carra, Carla Di Dato, Sergio Di Molfetta, Antonella Di Sarno, Giuseppe Fanciulli, Diego Ferone, Francesco Ferraù, Elisa Giannetta, Federica Grillo, Erika Maria Grossrubatscher, Elia Guadagno, Andrea Isidori, Fabio Lo Calzo, Pasqualino Malandrino, Chiara Martini, Erika Messina, Roberta Modica, Giovanna Muscogiuri, Genoveffa Pizza, Paola Razzore, Laura Rizza, Rosaria Maddalena Ruggeri, Concetta Sciammarella, Giovanni Vitale, and Maria Chiara Zatelli.
All authors have contributed equally to the conception and design of the review. MG, FDC, VG, and MR analyzed data and drafted the article. AF and AC revised the manuscript critically. All authors approved the final article.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
This article does not contain any studies with human participants or animals performed by any of the authors.
- BAVENCIO (avelumab) (2018) Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004338/WC500236647.pdf. Accessed 18 Oct 2018
- Becker JC, Lorenz E, Ugurel S, Eigentler TK, Kiecker F, Pföhler C et al (2017) Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget 8:79731–79741. https://doi.org/10.18632/oncotarget.19218 CrossRefPubMedPubMedCentralGoogle Scholar
- Bhatia S, Miller N, Lu H, Ibrani D, Shinohara M, Byrd DR et al (2016) Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME). 2016 ASCO Annual Meeting. J Clin Oncol 34(15 suppl):3021CrossRefGoogle Scholar
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) National comprehensive cancer network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385 CrossRefPubMedGoogle Scholar
- Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH et al (2014) Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2:27–36. https://doi.org/10.1158/2326-6066.CIR-13-0087 CrossRefPubMedGoogle Scholar
- D’Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ et al (2018) Efficacy and Safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.0077 CrossRefPubMedPubMedCentralGoogle Scholar
- Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:522–530. https://doi.org/10.1016/S1470-2045(15)70122-1 CrossRefPubMedPubMedCentralGoogle Scholar
- El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2 CrossRefPubMedGoogle Scholar
- Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A et al (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078–4085. https://doi.org/10.1210/jc.2014-2306 CrossRefPubMedGoogle Scholar
- Felicetti F, Nervo A, Piovesan A, Berardelli R, Marchisio F, Gallo M et al (2017) Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther 17(12):1093–1098. https://doi.org/10.1080/14737140.2017.1390432 CrossRefPubMedGoogle Scholar
- Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M et al (2010) Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res BCR 12(4):R48. https://doi.org/10.1186/bcr2605 httpsCrossRefPubMedGoogle Scholar
- Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L et al (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:712–720. https://doi.org/10.1158/1078-0432.CCR-14-2468 CrossRefPubMedGoogle Scholar
- Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983. https://doi.org/10.1016/S1470-2045(16)30053-5 CrossRefPubMedPubMedCentralGoogle Scholar
- Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J et al (2018) ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdy162 CrossRefPubMedPubMedCentralGoogle Scholar
- Iwasaki T, Matsushita M, Nonaka D, Kuwamoto S, Kato M, Murakami I et al (2015) Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas. Hum Pathol 46(2):210–216. https://doi.org/10.1016/j.humpath.2014.07.025 CrossRefPubMedGoogle Scholar
- Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A et al (2016) Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer 4:60. https://doi.org/10.1186/s40425-016-0166-5 (eCollection 2016)CrossRefPubMedPubMedCentralGoogle Scholar
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374–1385. https://doi.org/10.1016/S1470-2045(16)30364-3 CrossRefPubMedPubMedCentralGoogle Scholar
- Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP et al (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6:7. https://doi.org/10.1186/s40425-017-0310-x CrossRefPubMedPubMedCentralGoogle Scholar
- Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N et al (2018) Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. https://doi.org/10.1002/cncr.31293 CrossRefPubMedPubMedCentralGoogle Scholar
- KEYTRUDA (pembrolizumab) (2018) Summary of product characteristics. https://www.ema.europa.eu/documents/product-information/keytruda-epar-product-information_en.pdf. Accessed 18 Oct 2018
- Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D et al (2017) Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol 3(11):1511–1519. https://doi.org/10.1001/jamaoncol.2017.1588 CrossRefPubMedPubMedCentralGoogle Scholar
- Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS et al (2017) Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer 5(1):66. https://doi.org/10.1186/s40425-017-0273-y CrossRefPubMedPubMedCentralGoogle Scholar
- Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC (2017) Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 13:1263–1279. https://doi.org/10.2217/fon-2017-0072 CrossRefPubMedPubMedCentralGoogle Scholar
- Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Friedlander PA et al (2018) Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. 2018 ASCO Annual Meeting. J Clin Oncol 36(15 suppl):9506CrossRefGoogle Scholar
- OPDIVO (nivolumab) (2018) Summary of product characteristics. https://www.ema.europa.eu/documents/product-information/opdivo-epar-product-information_en.pdf. Accessed 18 Oct 2018]
- Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75(23):5034–5045. https://doi.org/10.1158/0008-5472.can-14-3098 CrossRefPubMedGoogle Scholar
- Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4 CrossRefPubMedPubMedCentralGoogle Scholar
- Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P et al (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. https://doi.org/10.1002/ajh.25154 CrossRefPubMedGoogle Scholar
- Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC et al (2010) A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). Am J Clin Oncol 33(5):495–499. https://doi.org/10.1097/COC.0b013e3181b9cf04 CrossRefPubMedPubMedCentralGoogle Scholar
- Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903. https://doi.org/10.1016/S1470-2045(17)30380-7 CrossRefPubMedPubMedCentralGoogle Scholar
- Tarabadkar ES, Thomas H, Blom A, Parvathaneni U, Olencki T, Nghiem P et al (2018) Clinical benefit from tyrosine kinase inhibitors in metastatic merkel cell carcinoma: a case series of 5 patients. Am J Case Rep 19:505–511. https://doi.org/10.12659/AJCR.908649 CrossRefPubMedPubMedCentralGoogle Scholar
- Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H et al (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705. https://doi.org/10.1371/journal.pone.0087705 CrossRefPubMedPubMedCentralGoogle Scholar
- Toker C (1972) Trabecular carcinoma of the skin. Arch Dermatol 105:107–110. https://doi.org/10.1001/archderm.1972.01620040075020 CrossRefPubMedGoogle Scholar
- Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, MDX010-20 Investigators (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675–1682. https://doi.org/10.1002/cncr.27969 CrossRefPubMedGoogle Scholar
- Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B et al (2016) Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci 107(11):1563–1571. https://doi.org/10.1111/cas.13072 CrossRefPubMedPubMedCentralGoogle Scholar